Identification of Quinoline Tethered Thiadiazole/Thiazole Derivatives as Potent Tyrosinase Inhibitors With Promising Anti‐ Toxoplasma gondii Agents: Design, Synthesis, and Computational Analysis
Drug Development Research · 2026-08 · 87 (5)
DOI: 10.1002/ddr.70334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 18.06.2026. Verfasst von Ahmed Sabt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt. Hauptthemen laut MEDLINE: Thiazoles, Toxoplasma, Quinolines, Monophenol Monooxygenase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Ministry of Science and Higher Education, POLOPENSCREEN, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
Toxoplasmosis, caused by the protozoan parasite Toxoplasma gondii , remains a serious global health concern, largely because current treatments with sulfonamides and pyrimethamine are toxic and increasingly ineffective due to rising drug resistance. In response, this study describes the design, synthesis, and laboratory evaluation of novel hybrid molecules that merge a quinoline backbone with either thiadiazole (compounds 8a – e ) or thiazole (compounds 12a – d ) bioactive groups to develop safer and more effective therapies. Cytotoxicity tests on mouse (L929) and human (Hs27) fibroblast cell lines revealed distinct safety profiles: the thiadiazole hybrids ( 8a – e ) were significantly toxic to host cells, whereas the thiazole‐based versions ( 12a – d ) were much safer, with several showing no toxicity even at 250 µg/mL. When tested against T. gondii , the quinoline‐thiazole hybrids proved the most effective. Notably, 12b and 12c achieved IC 50 values of 0.40 and 0.52 µg/mL, respectively, better than the reference drug pyrimethamine (IC 50 = 0.74 µg/mL). Compound 12c emerged as the top candidate, with an excellent selectivity index (SI) of 71.0 in human Hs27 cells. Further mechanistic work showed that 12c strongly inhibits tyrosinase, a potential parasitic target. Kinetic studies revealed a mixed‐type inhibition mechanism, with an IC 50 of approximately 5 µM, 10 times more potent than kojic acid (48 µM), a standard inhibitor. Molecular docking and dynamics simulations confirmed stable binding between 12c and tyrosinase. Together, these findings underscore the therapeutic promise of the quinoline‐thiazole scaffold, particularly compound 12c , as a lead for developing targeted, low‐toxicity anti‐toxoplasmosis drugs. The results are expected to expand the existing toolkit of small molecules targeting the parasite and reinforce the importance of molecular hybridization in drug development. Additional research is needed to clarify how these compounds work and to assess their effectiveness in living organisms in order to fully unlock their potential as anti‐parasitic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt.
- Department of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
- Department of Therapeutic Chemistry, National Research Centre, Cairo, Egypt.
- Department of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, Lodz, Poland.
- Pesticide Chemistry Department, Chemical Industries Research Institute, National Research Centre, Cairo, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafr El Sheikh, Egypt.
ORCID-Profile: Ahmed Sabt, Aladdin M Srour, Hoda Atef Abdelsattar Ibrahim, Asmaa Saleh, Huda R M Rashdan
Förderung
- Ministry of Science and Higher Education, POLOPENSCREEN
- Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
Zitieren
APA
Sabt, A., Chyb, M., Srour, A. M., Bekier, A., Farag, H., Shaldam, M. A., Ibrahim, H. A. A., Saleh, A., Gatkowska, J., Rashdan, H. R. M., & Dziadek, J. (2026). Identification of Quinoline Tethered Thiadiazole/Thiazole Derivatives as Potent Tyrosinase Inhibitors With Promising Anti‐ Toxoplasma gondii Agents: Design, Synthesis, and Computational Analysis. Drug Development Research, 87(5). https://doi.org/10.1002/ddr.70334
Vancouver
Sabt A, Chyb M, Srour AM, Bekier A, Farag H, Shaldam MA, et al. Identification of Quinoline Tethered Thiadiazole/Thiazole Derivatives as Potent Tyrosinase Inhibitors With Promising Anti‐ Toxoplasma gondii Agents: Design, Synthesis, and Computational Analysis. Drug Development Research. 2026;87(5). doi:10.1002/ddr.70334
BibTeX
@article{Sabt2026,
author = {Sabt, Ahmed and Chyb, Maciej and Srour, Aladdin M and Bekier, Adrian and Farag, Hanaa and Shaldam, Moataz A and Ibrahim, Hoda Atef Abdelsattar and Saleh, Asmaa and Gatkowska, Justyna and Rashdan, Huda R M and Dziadek, Jarosław},
title = {Identification of Quinoline Tethered Thiadiazole/Thiazole Derivatives as Potent Tyrosinase Inhibitors With Promising Anti‐ Toxoplasma gondii Agents: Design, Synthesis, and Computational Analysis},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {5},
doi = {10.1002/ddr.70334}
}
EUVIMED